<DOC>
	<DOCNO>NCT02123004</DOCNO>
	<brief_summary>1 . Ticagrelor inhibit inflammation improve vascular endothelial cell function great extent clopidogrel ST-segment elevation myocardial infarction ( STEMI ) patient receive percutaneous coronary intervention . 2 . Ticagrelor reduce serum level inflammatory biomarkers coronary peripheral venous patient ST-segment elevation myocardial infarction ( STEMI ) .</brief_summary>
	<brief_title>Comparison Ticagrelor And Clopidogrel Inflammatory Biomarkers And Vascular Endothelial Function</brief_title>
	<detailed_description>Platelet participate process form extend atherosclerotic plaque , also source inflammatory mediator . This study randomize , open-label study , design test hypothesis ticagrelor inhibit inflammation improve vascular endothelial cell function great extent clopidogrel ST-segment elevation myocardial infarction ( STEMI ) patient receive percutaneous coronary intervention . Patients schedule undergo emergency Percutaneous Coronary Intervention ( PCI ) randomly assign receive ticagrelor 180mg treatment group clopidogrel 600mg control group , Percutaneous Coronary Intervention ( PCI ) treatment group treat ticagrelor 90mg twice daily control group receive clopidogrel 75mg day . All patient receive Acetylsalicylic Acid ( ASA ) 300 mg load dose Percutaneous Coronary Intervention ( PCI ) 100 mg daily unless intolerant . Glycoprotein Ⅱb/Ⅲa receptor antagonists low-molecular-weight heparin additional medication direct treat cardiologist . All intervention perform via radial approach standard technique within 12h involved , drug-eluting stent place accord stenosis coronary artery . The vascular endothelial function test Circulating Endothelial Cells ( CECs ) level inflammation test CD40 ligand ( CD40L ) , C-reactive protein ( CRP ) , P-selectin identify ticagrelor inhibit inflammation improve vascular endothelial cell function great extent clopidogrel .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Male nonpregnant female . 2 . Age ≥ 18 year old ＜80 year old . 3 . Consecutive patient hospitalize documented evidence STSegment Elevation Myocardial Infarction receive Percutaneous Coronary Intervention . 4 . All patient havepersistent≥0.2 Millivolt ST segment elevation two contiguous precordial lead ≥0.1 Millivolt ST elevation two contiguous limb lead , one following : persistent chest pain elevatory biomarkers myocardial necrosis . 5 . Time chest pain onset receive Percutaneous Coronary Intervention &lt; 12 hour . 6 . Persistent chest pain &lt; 12 hour . 7 . Provision inform consent prior study specific procedure . 1 . Involved trial . 2 . In recent one year P 2 Y 12 receptor antagonist drug treatment history longterm use immunosuppressive agent . 3 . Recurrent myocardial infarction previous history Coronary Artery Bypass Graft ( CABG ) surgery rescue Percutaneous Coronary Intervention . 4 . Active bleed bleed history . 5 . With obvious infection body temperature ( axillary temperature ) high 38.0 ℃ . 6 . Autoimmune diseases . 7 . Malignancies . 8 . In recent 6 month receive major surgery . 9 . Left ventricular ejection fraction le 30 % . 10 . Life expectancy less one year . 11 . With moderate severe liver function deterioration . 12 . Endstage renal failure . 13 . Other condition may put patient risk influence study result investigator ' opinion：eg , increase risk bradycardiac event ; know clinically important thrombocytopenia ; know clinically important anemia ; severe hemodynamic instability . 14 . Other contraindication investigate product . 15 . Any condition increase risk noncompliance lose followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ST-Segment Elevation Myocardial Infarction</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>